ARIA
Library/metabolic/Tirzepatide

Tirzepatide

FDA Approved✓ WADA Permitted

Mounjaro / Zepbound

metabolic✓FDA ApprovedDual GIP/GLP-1 receptor agonist

First dual GIP/GLP-1 receptor agonist. Superior weight loss vs GLP-1 RAs alone. Up to 22.5% weight loss in SURMOUNT-1. Approved for T2DM (Mounjaro) and obesity (Zepbound).

Confidence
97%
Half-Life ~5 days
Cost ~$1200/mo
Quick Reference
Routesubcutaneous
MechanismDual agonist at GIP and GLP-1 receptors. Enhanced insulin secretion, reduced glu...
SequenceYGEGTFTSDYSIALEKIAKEFIEWLVKGGG
Mol. Weight4810.5 Da
Reviewed2026-07-08

Mechanism of Action

Dual agonist at GIP and GLP-1 receptors. Enhanced insulin secretion, reduced glucagon, slowed gastric emptying, appetite suppression. GIP component may increase energy expenditure and improve fat metabolism.

Dosing Protocol

Zepbound: 2.5mg/wk x4 → 5mg → 7.5mg → 10mg → 12.5mg → 15mg (max). Titrate q4wk.

Key Studies

2022

SURMOUNT-1: Tirzepatide for obesity

PMID 35133369rct
2026

GLP-1 RA reduces knee OA arthroplasty risk

PMID 42229941cohort
2025

Tirzepatide dermatology and cosmetic implications

PMID 41483501review

Adverse Effects

Nausea (30%)Diarrhea (20%)Vomiting (15%)ConstipationInjection site reactionsDyspepsiaPotential hair loss

Contraindications

  • Personal/FHx medullary thyroid carcinoma
  • MEN2 syndrome
  • Hypersensitivity
  • Pregnancy

Storage

Refrigerate at 2-8°C. Protect from light. Once opened, use within 56 days.

Clinical Applications

  • ["weight_management"
  • "type_2_diabetes"
  • "metabolic_syndrome"
  • "body_contouring_preparation"]